Literature DB >> 26252918

Manifestations of Cow's-Milk Protein Intolerance in Preterm Infants.

Jonathan Cordova1, Sudhir Sriram, Tiffany Patton, Hillary Jericho, Ranjana Gokhale, Dana Weinstein, Timothy Sentongo.   

Abstract

OBJECTIVES: Cow's-milk protein intolerance (CMPI) is poorly recognized in preterm infants. This study examined the clinical events that preceded the diagnosis of CMPI in preterm infants.
METHODS: This was a retrospective study of infants in a level-III neonatal intensive care unit of those who received parenteral nutrition (PN) support during a 12-month period. Parameters assessed included birth weight (g), diagnosis, duration and frequency on PN, type of enteral feeds at initiation, and achievement of enteral autonomy. CMPI was diagnosed based on persistent feeding intolerance that resolved after change of feeds from intact protein to a protein hydrolysate or crystalline amino acid formula.
RESULTS: Three hundred forty-eight infants with birth weight (median/range) 1618 g (425-5110) received PN. Fifty-one (14%) infants required multiple courses of PN, and 19 of 348 (5%) were diagnosed with CMPI. The requirement for multiple courses on PN versus single course was associated with a high likelihood of CMPI: 14 of 51 versus 5 of 297, P < 0.001. Nine of the 14 infants identified with CMPI were initially diagnosed with necrotizing enterocolitis (NEC) after a median duration of 22 days (19-57) on intact protein feeds. After recovery from NEC, they had persistent feeding intolerance including recurrence of "NEC-like illness" (N = 3) that resolved after change of feeds to a protein hydrolysate or crystalline amino acid formula.
CONCLUSIONS: The requirement for multiple courses of PN because of persistent feeding intolerance after recovery from NEC and recurrence of "NEC-like illness" may be a manifestation of CMPI in preterm infants.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26252918     DOI: 10.1097/MPG.0000000000000933

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  6 in total

1.  Human Milk-Derived Fortifiers Compared with Bovine Milk-Derived Fortifiers in Preterm Infants: A Systematic Review and Meta-Analysis.

Authors:  Anitha Ananthan; Haribalakrishna Balasubramanian; Shripada Rao; Sanjay Patole
Journal:  Adv Nutr       Date:  2020-09-01       Impact factor: 8.701

Review 2.  Spontaneous intestinal perforation (SIP) will soon become the most common form of surgical bowel disease in the extremely low birth weight (ELBW) infant.

Authors:  Jonathan R Swanson; Amy Hair; Reese H Clark; Phillip V Gordon
Journal:  J Perinatol       Date:  2022-02-17       Impact factor: 2.521

3.  Effect of Maternal Diet on Any Necrotizing Enterocolitis in Neonates: A Randomized Double-Blind Study.

Authors:  Nasrin Khalesi; Narges Mazloomi Nobandegani; Nastaran Khosravi; Maryam Saboute; Seyyede Faride Farahi; Zinat Shakeri; Leila Allahqoli; Ibrahim Alkatout
Journal:  Breastfeed Med       Date:  2022-05-25       Impact factor: 2.335

4.  A Preterm Case of Cow's Milk Allergy Presenting with Recurrent Ascites Treated with Donor Breast Milk.

Authors:  Ruka Nakasone; Kazumichi Fujioka; Shutaro Suga; Shinya Abe; Mariko Ashina; Kosuke Nishida; Motoichiro Sakurai; Katsumi Mizuno; Kandai Nozu; Kazumoto Iijima
Journal:  Int J Environ Res Public Health       Date:  2021-01-29       Impact factor: 3.390

5.  Clinical Observation of Extensively Hydrolysis Protein Formula With Feeding Intolerance in Preterm Infants.

Authors:  Liping Yin; Jingjing Ma; Heng Liu; Qianying Gu; Li Huang; Qi Mu; Ning An; LiJuan Qian; Lixing Qiao
Journal:  Front Pediatr       Date:  2022-06-13       Impact factor: 3.569

6.  Newborns with Bloody Stools-At the Crossroad between Efficient Management of Necrotizing Enterocolitis and Antibiotic Stewardship.

Authors:  Marie Heyne-Pietschmann; Dirk Lehnick; Johannes Spalinger; Franziska Righini-Grunder; Michael Buettcher; Markus Lehner; Martin Stocker
Journal:  Antibiotics (Basel)       Date:  2021-11-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.